LONDON—A large clinical trial run by GlaxoSmithKline PLC has failed to show that the company's Breo Ellipta inhaler extends life in patients with chronic obstructive pulmonary disease, dashing hopes of a sales boost for the product.

Glaxo had hoped that the so-called Summit study, which tested Breo against a placebo in 16,485 patients from 43 countries, would demonstrate that the product prolonged life as well as helped with breathing.

Summit was the first study to test the effect on survival of inhaler products like Breo, which open up the airways to ease breathing in patients with asthma or COPD. It enrolled patients at higher risk of cardiovascular disease to see if Breo could bring added survival benefits to this group. About half of the people diagnosed with COPD are at heightened risk of cardiovascular disease.

The company said patients on Breo were 12.2% less at risk of dying than those on the placebo, but the difference wasn't large enough to be significant. The drug also reduced the rate of lung infections and heart problems, but Glaxo said it couldn't draw any solid conclusions from those secondary studies.

Eric Dube, head of Glaxo's global respiratory franchise, said the study nonetheless was important as the full data set would be "beneficial and informative to the respiratory and cardiovascular scientific community."

Still, the results are a blow to Glaxo. A positive result could have boosted sales of Breo by encouraging doctors to prescribe the drug over others in patients with higher cardiovascular risk. Breo is one of the drugs Glaxo is betting on to increase sales as its older blockbusters lose patent protection, but the drug's market share hasn't grown as quickly as expected because U.S. insurers have been slow to cover the drug.

Glaxo launched Breo in 2013 as a treatment for COPD, under the name Relvar Ellipta, and the European Medicines Agency also approved it for use in adults with asthma.

Write to Denise Roland at Denise.Roland@wsj.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

(END) Dow Jones Newswires

September 08, 2015 17:35 ET (21:35 GMT)

Copyright (c) 2015 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more GSK Charts.
GSK (NYSE:GSK)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more GSK Charts.